A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form.

ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profilingPoster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / ACCESS ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

The FDA has approved Nubeqa (darolutamide), an androgen receptor inhibitor, for the treatment of mCSPC in adults.

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...